CDC Recommendations for Measles Outbreak Management
During a measles outbreak, immediately implement a comprehensive vaccination program with MMR vaccine for all susceptible individuals in the affected setting, combined with strict exclusion of unvaccinated persons until 21 days after the last case. 1
Core Outbreak Control Strategy
The CDC's approach to measles outbreak control centers on rapid identification, vaccination, and exclusion protocols that vary by setting:
Preschool-Aged Children and Infants
- Infants 6-11 months: May receive early measles vaccination (monovalent preferred, MMR acceptable) if cases are occurring in this age group 1
- These children require revaccination at 12-15 months and again before school entry
- For household contacts under 12 months: Immune globulin (IG) is preferred over vaccination due to likely exposure >72 hours before diagnosis and higher complication risk 1
- Critical caveat: IG should NOT be used for general outbreak control—only for specific high-risk exposures 1
Day Care Facilities and Schools
All attendees, siblings, and personnel born during or after 1957 without documentation of two doses of measles vaccine or other immunity evidence must be revaccinated or excluded 1
The exclusion protocol is strict:
- Persons refusing vaccination or claiming exemptions must be excluded until 21 days after rash onset in the last case 1
- Revaccinated persons may return immediately 1
- Consider extending vaccination to unaffected facilities in the same geographic area at risk 1
Healthcare Settings
All healthcare workers without documentation of two doses of MMR vaccine (regardless of birth year during outbreaks) should receive MMR vaccine 1
Key healthcare-specific measures:
- Do NOT perform serologic testing before vaccination during outbreaks—this delays critical rapid vaccination needed to stop transmission 1
- Exposed susceptible healthcare workers: Remove from patient contact from day 5 through day 21 post-exposure, even if they receive post-exposure IG 1
- Workers born before 1957 should be strongly considered for vaccination during outbreaks, as they have transmitted measles in healthcare facilities despite presumed immunity 1
Evidence of Immunity (Acceptable Documentation)
The 2013 ACIP update removed physician-diagnosed disease as acceptable evidence and now requires 2:
- Laboratory confirmation of disease, OR
- Two documented doses of MMR vaccine (≥28 days apart, first dose ≥12 months of age), OR
- Serologic evidence of immunity
Important change: Physician diagnosis alone is no longer sufficient 2
Post-Exposure Prophylaxis Updates
Recent CDC guidance expanded immunoglobulin recommendations 2:
- IGIM now includes infants birth to 6 months exposed to measles
- Increased IGIM doses for immunocompetent persons
- IGIV recommended for severely immunocompromised persons and pregnant women without immunity who are exposed
Special Populations: HIV-Infected Persons
Expanded recommendations now include 2:
- All persons ≥12 months with HIV without current severe immunosuppression should receive MMR
- Those with perinatal HIV vaccinated before effective antiretroviral therapy (ART) should be revaccinated with 2 doses once ART is established
- Timing: 12-15 months and 4-6 years (same as general population)
Common Pitfalls to Avoid
- Do not delay vaccination for serologic testing during outbreaks—this impedes rapid control 1
- Do not use IG for mass outbreak control—reserve for specific high-risk exposures 1
- Do not assume healthcare workers born before 1957 are immune—they have transmitted measles in outbreaks 1
- Do not accept physician diagnosis as evidence of immunity—laboratory confirmation is now required 2
Current Context
While the provided guidelines are from 1998-2013, they remain the foundational CDC/ACIP recommendations. Recent literature confirms ongoing measles resurgence with 2,065 cases in 2025 in the United States 3, driven by vaccine hesitancy and pandemic-related disruptions. The two-dose MMR vaccine remains the only effective prevention strategy, as no FDA-approved antiviral exists 3.